BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 953 filers reported holding BAXTER INTL INC in Q1 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2018 | $245,000 | -28.4% | 3,719 | -16.2% | 0.05% | -29.2% |
Q3 2018 | $342,000 | +4.3% | 4,438 | 0.0% | 0.07% | -5.3% |
Q2 2018 | $328,000 | -3.5% | 4,438 | -15.2% | 0.08% | -3.8% |
Q1 2018 | $340,000 | -38.6% | 5,231 | -38.9% | 0.08% | -41.9% |
Q4 2017 | $554,000 | +4.5% | 8,560 | +1.3% | 0.14% | -73.2% |
Q3 2017 | $530,000 | -10.3% | 8,447 | -13.5% | 0.51% | -11.8% |
Q2 2017 | $591,000 | -27.6% | 9,769 | -38.0% | 0.58% | -31.4% |
Q1 2017 | $816,000 | -27.3% | 15,750 | -37.7% | 0.84% | -38.5% |
Q4 2016 | $1,122,000 | -20.4% | 25,290 | -14.6% | 1.36% | -9.6% |
Q3 2016 | $1,410,000 | -9.6% | 29,602 | -14.1% | 1.51% | -2.0% |
Q2 2016 | $1,559,000 | -5.6% | 34,471 | -14.3% | 1.54% | -7.1% |
Q1 2016 | $1,652,000 | +1.8% | 40,213 | -5.4% | 1.66% | -15.5% |
Q4 2015 | $1,622,000 | +15.9% | 42,505 | -0.3% | 1.96% | +2.2% |
Q3 2015 | $1,400,000 | -47.9% | 42,623 | +10.9% | 1.92% | -50.9% |
Q2 2015 | $2,688,000 | +5.4% | 38,427 | +3.2% | 3.90% | -3.4% |
Q1 2015 | $2,551,000 | +29.4% | 37,236 | +38.4% | 4.04% | -13.0% |
Q4 2014 | $1,972,000 | +97.4% | 26,904 | +93.2% | 4.64% | -2.2% |
Q3 2014 | $999,000 | +79.7% | 13,922 | +81.2% | 4.75% | +2.5% |
Q2 2014 | $556,000 | +0.4% | 7,685 | +2.1% | 4.63% | -4.4% |
Q1 2014 | $554,000 | +14.5% | 7,524 | +8.2% | 4.84% | +17.8% |
Q4 2013 | $484,000 | +26.4% | 6,957 | +19.4% | 4.11% | +7.3% |
Q3 2013 | $383,000 | – | 5,827 | – | 3.83% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |